Findings show accumulation of neuronal injury and functional decline suggesting that changes in gonadal hormones may be associated with changes in functional and biological markers in MS.
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
GlobalData on MSN4d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...
FOX 9 Minneapolis-St. Paul on MSN2d
Edina, Minnetonka high school basketball rivals team up to ‘beat’ MSThe Minnetonka and Edina Girls Basketball teams are rivals on the court, but now they are joining forces to defeat a common ...
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback